Does Humira Raise Infection Risk?
Yes, Humira (adalimumab) increases the risk of serious infections. It suppresses the immune system by blocking tumor necrosis factor (TNF), a protein involved in inflammation, which can impair the body's ability to fight bacteria, viruses, fungi, and tuberculosis.[1][2]
Patients on Humira face higher rates of infections like pneumonia, cellulitis, and sepsis compared to those not taking it. Clinical trials showed serious infections in 4% of Humira users versus 2% in placebo groups.[3]
What Types of Infections Are Most Common?
Upper respiratory infections occur in about 17% of users, sinusitis in 11%, and serious cases like tuberculosis reactivation or invasive fungal infections in 0.4-1%.[2][3] Opportunistic infections, such as histoplasmosis, are more frequent in endemic areas.[1]
Who Faces the Highest Risk?
Risk rises with age over 65, diabetes, prior infections, or concurrent immunosuppressants like methotrexate. Those with latent TB or chronic conditions like rheumatoid arthritis see amplified danger.[2][3]
How Do Doctors Manage This Risk?
Screen for TB, hepatitis B, and other infections before starting. Monitor for fever, cough, or weight loss during treatment. Live vaccines are contraindicated; discontinue Humira if serious infection develops.[1][2]
What Do Patients Report?
Real-world data from post-marketing surveillance confirms elevated risks, with some discontinuing due to infections. FDA black box warning highlights this since 2008.[3]
Alternatives with Lower Infection Risk?
Drugs like JAK inhibitors (e.g., Xeljanz) or non-TNF biologics (e.g., Rituxan) may have different profiles, but all immunomodulators carry infection warnings. Choice depends on condition and patient factors.[1]
[1]: FDA Humira Label
[2]: Humira Prescribing Information
[3]: Drugs.com Humira Side Effects